Trial Update November 9, 2026

Tesamorelin Phase 2 Nerve Injury Trial Status Updated Nov 9, 2026

On November 9, 2026, a clinical trial update was recorded for tesamorelin, an approved compound. The trial, titled "Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury," is registered as NCT03150511. It is listed as a Phase 2 study. According to the update, the trial status is recruiting. No results or outcome data were included in this update. The listing reflects only the trial's current administrative status as of the date given. This record does not state efficacy, safety findings, or conclusions about tesamorelin's effect on nerve injury recovery. Interested readers should consult the official registry listing for full eligibility criteria, study design, and sponsor details. For general background on tesamorelin, including its approved uses and regulatory status, readers can refer to the compound overview for additional context.

See the full tesamorelin overview

Source: https://clinicaltrials.gov/study/NCT03150511